A panel of experts on prostate cancer provide an overview of conventional imaging modalities that have been used in the initial staging and management of prostate cancer and discuss the role of PSMA-PET imaging.
Advances in Imaging for Prostate Cancer: The Role for PSMA-PET Imaging
A panel of experts on prostate cancer discuss the role for PSMA-PET imaging, highlighting clinical practices, recent advances, and key updates.
The panel discusses the role of PSMA-PET imaging in prostate cancer and highlights different PSMA agents.
Experts on prostate cancer offer clinical insights on identifying the appropriate patients for PSMA-PET imaging.
Steven Finkelstein, MD, FACRO, discusses PSMA-PET imaging practices for patients experiencing biochemical recurrence.
The panel discusses how PSMA-PET imaging informs treatment decisions for patients with prostate cancer.
Focusing on active surveillance of patients with prostate cancer, discussion centers around the role of PSMA-PET imaging and the implications of negative scans.
Experts on prostate cancer discuss the ideal timing and frequency of PSMA-PET imaging and the role of different PSMA-PET agents.
A panel of experts on prostate cancer share strategies for monitoring patients and discuss whether to use PSMA to monitor treatment response.
Prostate cancer specialists discuss challenges associated with imaging in clinical practice.
Experts on prostate cancer discuss the benefits to multidisciplinary care as it pertains to PSMA-PET imaging.
Looking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Tony Abraham, DO, MPA, discusses how the emergence of PSMA-PET imaging has impacted the staging and management of patients with prostate cancer.
A nuclear radiologist provides an overview of the gallium- and fluorine-based PSMA-PET tracer options, highlighting factors that influence tracer selection.
Tony Abraham, DO, MPA, outlines the limitations of PSMA-PET imaging and discusses the importance of multidisciplinary care in overcoming challenges surrounding the interpretation and reporting of imaging results.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Active Surveillance for Intermediate-risk Prostate Cancer, with Michael Leapman, MD, MHS
2
Christof Vulsteke, MD, PhD, breaks down findings, implications of KEYNOTE-905
3
The Significance of KEYNOTE-905 in Muscle-Invasive Bladder Cancer
4
Petros Grivas, MD, on the significance of a perioperative regimen for cisplatin-ineligible MIBC
5
